<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943914</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/62</org_study_id>
    <nct_id>NCT03943914</nct_id>
  </id_info>
  <brief_title>Early Non-invasive Ventilation and High-flow Nasal Oxygen Therapy for Preventing Delayed Respiratory Failure in Hypoxemic Blunt Chest Trauma Patients.</brief_title>
  <acronym>OptiTHO</acronym>
  <official_title>Early Non-invasive Ventilation and High-flow Nasal Oxygen Therapy for Preventing Delayed Respiratory Failure in Hypoxemic Blunt Chest Trauma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In blunt chest trauma patients without immediate life-threatening conditions, delayed
      respiratory failure and need for mechanical ventilation may still occur in 12 to 40% of
      patients, depending on the severity of the trauma, the preexisting conditions and the
      intensity of initial management.

      In this context, non-invasive ventilation (NIV) is recommended in hypoxemic chest trauma
      patients, defined as a PaO2/FiO2 ratio &lt; 200 mmHg. However, there is a large heterogeneity
      among studies regarding the severity of injuries, the degree of hypoxemia and the timing of
      enrollment. The interest of a preventive strategy during the early phase of blunt chest
      trauma, before the occurrence of respiratory distress or severe hypoxemia, is not formally
      established in the literature. Moreover, high-flow nasal oxygen therapy (HFNC-O2) appears to
      be a reliable and better tolerated alternative to conventional oxygen therapy (COT),
      associated with a significant reduction in intubation rate in hypoxemic patients.

      Two NIV strategies are compared:

        1. In the experimental strategy, NIV is performed after inclusion in patients with moderate
           hypoxemia, defined by a PaO2/FiO2 ratio &lt; 300 mmHg. The minimally required duration of
           NIV was 4 hours per day for at least 2 calendar days.

        2. In the control group, patients receive oxygen from nasal cannula or high concentration
           oxygen mask according to the FiO2 needed to achieve SpO2 &gt; 92%. NIV is initiated only in
           patients having PaO2/FiO2 ratio &lt; 200 mmHg under COT.

      Investigators hypothesized that an early strategy associating HFNC-O2 and preventive NIV in
      hypoxemic blunt chest trauma patients may reduce the need for mechanical ventilation compared
      to the recommended strategy associating COT and late NIV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Necessity to perform endotracheal intubation</measure>
    <time_frame>Up to 14 days after randomization</time_frame>
    <description>To ensure the consistency of indications across sites and reduce the risk of delayed intubation, the following criteria for endotracheal intubation must be used (only one criterion is needed): cardiac arrest or significant hemodynamic instability, deterioration of neurologic status, signs of persisting or worsening respiratory failure as defined by at least two of the following criteria: respiratory rate of more than 35 breaths per minute, lack of improvement in signs of high respiratory-muscle workload, development of copious tracheal secretions, signs of respiratory exhaustion (pH &lt;7.32 or PaCO2 &gt; 50 mmHg), major hypoxemia (PaO2/FiO2 ratio &lt;100 or SpO2 &lt;92% for more than 5 minutes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>every 6 hours during the first 48 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>every 6 hours during the first 48 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>every 6 hours during the first 48 hours after randomization</time_frame>
    <description>Dyspnea score : +2 = significant improvement; +1 = slight improvement; 0 = no change; -1 = slight deterioration ; -2 = significant deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length of stay</measure>
    <time_frame>Up to 14 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU or in-hospital mortality</measure>
    <time_frame>Up to 14 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator free-days</measure>
    <time_frame>Up to 14 days after randomization</time_frame>
    <description>Days alive and without invasive or non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Chest Injuries</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>An &quot;early&quot; NIV strategy associated with HFNC-O2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A &quot;late&quot; NIV strategy associated with COT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Preventive strategy</intervention_name>
    <description>In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio &lt; 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate &lt; 25/min and SpO2 &gt; 92% under FiO2 &lt; 30% for at least 6 hours.</description>
    <arm_group_label>An &quot;early&quot; NIV strategy associated with HFNC-O2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 &gt; 92%. NIV is initiated only in patients having PaO2/FiO2 ratio &lt; 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.</description>
    <arm_group_label>A &quot;late&quot; NIV strategy associated with COT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient admitted in intensive care unit within 48 hours after a high-risk blunt chest
             trauma, defined by a TTS (Thorax Trauma Severity) score ≥ 8.

          -  Hypoxemia defined by a PaO2/FiO2 ratio &lt; 300, and the absence of hypercapnia (PaCO2 &lt;
             45 mmHg).

          -  Without indication of endotracheal intubation at inclusion.

          -  Affiliated person or beneficiary of a social security scheme.

          -  Free, informed and written consent signed by the participant and the investigator (at
             the latest on the day of inclusion and before any examination required by the
             research).

        Exclusion Criteria:

          -  Criteria relating to formal indication to NIV: Exacerbation of underlying chronic
             respiratory disease, cardiogenic pulmonary edema, severe neutropenia.

          -  Criteria relating to contraindications to NIV: Hemodynamic instability, Glasgow Coma
             Scale score ≤ 12 or excessive agitation, or other contraindications to non-invasive
             ventilation (active gastrointestinal bleeding, low level of consciousness, multiorgan
             failure, airway patency problems, lack of cooperation or hemodynamic instability).

          -  Associated traumatic lesions entailing particular risks: severe brain injury, complex
             facial trauma, tetraplegia, tracheobronchial or esophageal injuries, thoracic or
             abdominal trauma with indication for surgery by thoracotomy or laparotomy.

          -  Criteria relating to the regulation: A do-not-intubate order and a decision not to
             participate, persons placed under judicial protection, persons participating in
             another research including a period of exclusion still in course, severely altered
             physical and/or psychological health which, according to the investigator, could
             affect the participant's compliance of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine BENARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique (USMR) du CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu BIAIS, MD-PhD</last_name>
    <phone>05 57 82 10 19</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.biais@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cédric CARRIE, MD</last_name>
    <phone>05 56 79 55 95</phone>
    <phone_ext>+33</phone_ext>
    <email>cedric.carrie@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé DUPONT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hervé DUPONT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric CARRIE, MD</last_name>
      <email>cedric.carrie@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu BIAIS, MD-PhD</last_name>
      <email>matthieu.biais@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cédric CARRIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu BIAIS, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GODET, MD</last_name>
      <email>tgodet@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor JURCISIN, MD</last_name>
      <email>igor.jurcisin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Igor JURCISIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Libourne</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert GRAND, Dr</last_name>
      <email>hubert.grand@ch-libourne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc GAINNIER, MD-PhD</last_name>
      <email>marc.gainnier@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Marc GAINNIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole ICHAI, MD-PhD</last_name>
      <email>ichai@unice.fr</email>
    </contact>
    <investigator>
      <last_name>Carole ICHAI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent MULLER, MD</last_name>
      <email>laurent.muller@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent MULLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Tenon</name>
      <address>
        <city>Paris 20</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel FARTOUKH, MD-PhD</last_name>
      <email>muriel.fartoukh@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Muriel FARTOUKH, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre MASSRI, MD</last_name>
      <email>alexandre.massri@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre MASSRI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Stéphane DAVID, MD-PhD</last_name>
      <email>jean-stephane.david@chulyon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Stéphane DAVID, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire DAHYOT-FIZELIER, MD-PhD</last_name>
      <email>claire.dahyot-fizelier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Claire DAHYOT-FIZELIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie REYNAUD SALARD, MD</last_name>
      <email>marie.reynaud@chu-stetienne.fr</email>
    </contact>
    <investigator>
      <last_name>Marie REYNAUD SALARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier COLLANGE, MD</last_name>
      <email>olivier.collange@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg -Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien POTTECHER, MD-PhD</last_name>
      <email>julien.pottecher@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Julien POTTECHER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Picqué</name>
      <address>
        <city>Villenave-d'Ornon</city>
        <zip>33882</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TRAN-VAN, MD</last_name>
      <email>david.tranvan@intradef.gouv.fr</email>
    </contact>
    <investigator>
      <last_name>David TRAN-VAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chest trauma</keyword>
  <keyword>Respiratory failure</keyword>
  <keyword>Noninvasive ventilation</keyword>
  <keyword>High-flow nasal oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Thoracic Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

